Drugs / STEMVAC
STEMVAC
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07078604 | Mar 2026 → Apr 2027 expected | female breast carcinoma, triple-negative breast carcinoma | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT05455658 | Nov 2022 → Jul 2026 overdue | female breast carcinoma, triple-negative breast carcinoma | University of Washington | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STEMVAC | “This phase II trial studies the effect of DNA plasmid based vaccine (STEMVAC) in treating patients with patients with stage IB-III triple negative breast cancer.” NCT05455658 ↗1“This phase II trial studies how well a cancer vaccine called STEMVAC works in combination with chemotherapy” NCT07078604 ↗ |
| Action | Deplete | “it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease” NCT07078604 ↗ |
| Modality | Vaccine | “DNA plasmid based vaccine (STEMVAC)” NCT05455658 ↗ |
| Route | Intravenous | “Given IV” NCT05455658 ↗ |
| Target | CDH3 | “A Phase II Trial of the Immunogenicity of a DNA Plasmid-Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells...” NCT07078604 ↗ |
| Target | MDM2 | “A Phase II Trial of the Immunogenicity of a DNA Plasmid-Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells...” NCT07078604 ↗ |
| Target | SOX2 | “A Phase II Trial of the Immunogenicity of a DNA Plasmid-Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells...” NCT07078604 ↗ |